Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06475820 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Baricitinib at Children and Young Adults With Hemoblastosis

StatusActive, Not Recruiting
PhasePhase 2/3
Started2023-12-01
View on ClinicalTrials.gov ↗

Amendment history

2024-08-22
Recruiting→Active, Not Recruiting Study Status, Contacts/Locations v1
Trial statusRecruiting→Active, Not Recruiting
Primary completion dateestimated 2026-12-01→confirmed 2024-07-01
Study sitesdetails revised at 1 of 1 site
2024-06-19
Original filing
GVHD prevention using a combination of post-transplantation cyclophosphamide in combination with abatacept, vedolizumab and and Baricitinib in children and young adults with hematoloblastosis after myeloablative conditioning regimen with treosulfan/TBI, cyclophosphamide/etoposide, fludarabine after HSCT from matched unrelated and haploidentical donors
Trial Details
NCT Number NCT06475820
Lead Sponsor Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Conditions Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Biphenotypic Acute Leukemia, Malignant Lymphoma, Myelodysplastic Syndromes
Enrollment 150 participants
Start Date 2023-12-01
Primary Completion 2024-07-01 (estimated)
Study Completion 2027-04-01 (estimated)
Updated on ClinicalTrials.gov 2024-08-23